Pregnancy hormone explored as possible guide for cardiovascular drug development

The STAT+ newsletter preview highlights a discussion about whether a hormone that regulates pregnancy could be leveraged to direct a new cardiovascular therapy.

The piece also notes that researchers in radiopharmaceuticals are testing higher dose levels, while concerns remain about safety and patient survival. It adds that recent skepticism toward mRNA technologies may be eased by emerging cancer vaccine approaches.

Overall, the article signals ongoing debate and experimental activity across several biotech areas, without reporting any specific regulatory decisions or trial results.